Mitsui Toatsu Chemicals, Incorporated

Mitsui Chemicals, Inc.

Mitsui Toatsu Kagaku Kabushiki Kaisha

Schering Aktiengesellschaft

Hajime Iizuka

Nobuyuki Fukazawa

Tsutomu Katakami

Takashi Nishina

Takuo Nakano

Hiroshi Kawazura

Joji Kamiya

Norio Ohto

Yasuhito Tanaka

Yoshio Shiga

Hiroyuki Yamashita

Osamu Yano

Kunio Okumura

Yukio Miyama

Naruyoshi Mita

Hiroshi Nagase

Takahisa Oguchi

Kazutoshi Horikomi

Seitaro Kajiya

Kazuya Sakai

Makoto Odate

Junya Fujiwara

Yasuhiro Takahashi

Hiroshi Namekawa

Takaichi Miwa

Tsuneji Suzuki

Hidetoshi Tsunoda

Kazuhiko Togashi

Michiru Sekiguchi

Takeshi Kamioka

Yoji Aoki

Shinji Takahashi

Isao Shirakawa

Shoji Kawashima

A novel method has been found to produce 2,2'-anhydro-1-(&#x3b2;-L-arabinofuranosyl)thymine as a novel useful intermediate compound. A novel method has been further found to produce thymidine from 2,2&#x2032;-anhydro-1-(&#x3b2;-L-arabinofuranosyl)thymine. A novel method has been further found to L-2&#x2032;-deoxyribose derivatives as a useful synthetic intermediate through L-2,2&#x2032;-anhydro-5,6-dihydrocyclouridine derivative. According to these methods, synthesis of various L-nucleic acid derivatives, synthesis of which has been difficult till now.

L-nucleic acid derivatives and process for the synthesis thereof

Amino acid N-carboxyanhydrides with acyl substituents on nitrogen atoms thereof

Method for production of pyrrolidinone derivatives

A compound represented by the following formula (12) useful as an intermediate for production of drug or agricultural chemical:

Since a compound represented by general formula (1), its pharmaceutically acceptable salt and a hydrate of the pharmaceutically acceptable salt have high antipsychotic activity, they may be used as an active ingredient for preparation of an antipsychotic. ##STR1## Also provided are an optical resolution method of the above compound and an intermediate for preparation of the compound.

Pyrrolidinone derivatives

Antipsychotics and ischemic cerebral disease therapeutics comprising as an effective ingredient a compound represented by the following formula (1) or (2): ##STR1## or a salt thereof. These drugs do not induce extrapyramidal side effects.

Amide derivatives of dihydrocaffeic acid and their application to

Dihydrocaffeic acid derivatives are here disclosed which are applicable as medicines having excellent absorbency in the case of oral administration and good concentration retention in blood. The disclosed compounds have the function to induce the production and secretion of a nerve growth factor (NGF) in the brain tissue, and therefore they are effective as medicines for the progression inhibition and therapy of regressive disorders of the central nervous system.

Dihydrocaffeic acid derivatives and pharmaceutical preparation

Dihydrocaffeic acid derivatives and pharmaceutical preparations

The present invention relates to a novel (-)-2-pyrazoline compound and therapeutic agents containing the same as an effective ingredient; furthermore, it relates to a method for optically resolving 1-(3-pyridylcarbonyl)-5-methyl-2-pyrazoline.

(-)-2-pyrazoline compounds and therapeutic agent for cerebrovascular

Method of optically resolving

2-Pyrazoline derivatives of the formula (A): ##STR1## where R.sup.1 is a pyridyl, a pyrazyl or an alkoxyl group; and R.sup.2 is a hydrogen atom, an alkyl, a pyridyl, a furyl, phenyl or a substituted phenyl group, and to a process for producing the same. Therapeutic agents for treating cerebrovascular diseases containing, as the active ingredient, a 2-pyrazoline derivative represented by the formula (G): ##STR2## where R.sup.3 is a hydrogen atom, an alkyl, acetyl, an alkoxycarbonyl, an amino, benzoyl, a substituted benzoyl, a pyridylcarbonyl, a furylcabonyl, a thienylcarbonyl, a pyrazylocarbonyl, an N-substituted carbamoyl, an N-substituted thiocarbamoyl, or carboxyl group; and R.sup.4 is a hydrogen atom, an alkyl, a pyridyl, a thienyl, a furyl, cyclohexyl, phenyl or a substituted phenyl group or a pharmaceutically acceptable salt thereof. These therapeutic agents cope with cerebral edemas in the acute stage of cerebral apoplexy and regulates the whole-body and intracranial body circulation, thereby protecting ischemic lesions and minimizing the spread to affected parts.

Pyrazolone derivatives for treating cerebrovascular diseases

This invention relates to pyridazinone derivatives of the general formula: ##STR1## [wherein R.sup.1 stands for a hydrogen atom or a lower alkyl group; R.sup.2 for a hydrogen atom or a lower alkyl group; and A for (i) a ring selected from a benzene ring, a furan ring, a thiophene ring and a pyridine ring (on which ring 1-3 substituents or atoms selected from amino groups, nitro groups, lower alkanoylamino groups, hydroxyl groups, lower alkanoyloxy groups, sulfamoyl groups and halogen atoms may be present), or (ii) a grouping of the formula: ##STR2## (wherein R.sup.3 stands for a hydrogen atom, a lower alkyl group, a phenyl(lower)alkyl, a hydroxyphenyl(lower)alkyl group, a lower alkylmercapto(lower)alkyl group, a benzylmercapto(lower)alkyl group, a guanidino(lower)alkyl group, a nitroguanidino(lower)alkyl group, an indolyl(lower)alkyl group, a carbamoyl(lower)alkyl group or a carboxy(lower)alkyl group, R.sup.4 for a hydrogen atom or a lower alkyl group, R.sup.5 for a hydrogen atom, a lower alkyl group, a lower alkanoyl group, a benzoyl or a benzyloxycarbonyl group, and R.sup.3 and R.sup.4 may be combined to form a grouping of the formula: ##STR3## which forms a ring), or (iii) a grouping of the formula: ##STR4## (wherein R.sup.6, R.sup.7 and R.sup.8 each stand for a hydrogen atom or a lower alkyl group, B is an oxygen atom or a sulfur atom, R.sup.9 stands for a hydrogen atom or a lower alkanoyl group, and n is 0 or 1)].

6-acylaminophenyl-5-alkyl-4,5-dihydro-3(2H)-pyridazinone compounds

1-Acyl-2-pyrazoline derivatives represented by the formula ##STR1## where R.sup.1 denotes a hydrogen atom, pyridyl group, pyrazinyl group, alkyl group, aryl group, or alkoxy group; and R.sup.2, R.sup.3, and R.sup.4 independently denote a hydrogen atom, furyl group, pyridyl group, alkyl group, or aryl group, are produced by cyclizing by heating an acylhydrazone derivative represented by the formula ##STR2## where R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined as above, to produce compounds having useful anti-cerebral edema activity.

Process for producing 1-acyl-2-pyrazoline derivative

2-Pyrazoline derivatives of the formula (A): ##STR1## where R.sup.1 is a pyridyl, a pyrazyl or an alkoxy group; and R.sup.2 is a hydrogen atom, an alkyl, a pyridyl, a furyl, phenyl or a substituted phenyl group, and to a process for producing the same. Therapeutic agents for treating cerebrovascular diseases containing, as the active ingredient, a 2-pyrazoline derivative represented by the formula (G): ##STR2## where R.sup.3 is a hydrogen atom, an alkyl, acetyl, an alkoxycarbonyl, an amino, benzoyl, a substituted benzoyl, a pyridylcarbonyl, a furylcarbonyl, a thienylcarbonyl, a pyrazylcarbonyl, an N-substituted carbamoyl, an N-substituted thiocarbamoyl, or carboxy group; and R.sup.4 is a hydrogen atom, an alkyl, a pyridyl, a thienyl, a furyl, cyclohexyl, phenyl or a substituted phenyl group or a pharmaceutically acceptable salt thereof. These therapeutic agents cope with cerebral edemas in the acute stage of cerebral apoplexy and regulates the whole-body and intracranial body circulation, thereby protecting ischemic lesions and minimizing the spread to affected parts.

Pyrazoline derivatives for treating cerebrovascular diseases

Growing community of inventors

Hiratsuka, Japan

Hajime Iizuka